Low rates of retained gastric contents were seen in endoscopy patients on GLP-1 receptor agonists ( RAs), a retrospective ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Discover how food brands can adapt to the rising GLP-1 trend. As weight-loss drugs reshape consumer habits, learn which ...

For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment ...

For patients with type 2 diabetes, GLP-1 RAs are associated with an increased risk for GERD and its complications compared with SGLT-2 inhibitors.

Estimated risk ratio was lower with GLP-1 receptor agonists for those younger than 75 years, but was no different for those aged 75 years or older ...

Popular GLP-1 drugs help many people drop tremendous amounts of weight, but the drugs fail to provide a key improvement in ...

GLP-1 drugs came out in 2005 as a Type 2 diabetes treatment. But in recent years their popularity for weight loss -- and the ...

A major new study reveals that older adults with cancer and type 2 diabetes who take GLP-1 receptor agonist medications (GLP-1RAs) experience significantly better overall survival rates compared to ...